What is CA 19-9?
CA 19-9 (carbohydrate antigen 19-9) is a tumor-associated antigen that exists as an epitope of sialylated Lewis A blood group antigen, originally identified using a monoclonal antibody from a human colorectal cancer cell line 1.
Biochemical Definition
CA 19-9 is a cell surface glycoprotein complex and tetrasaccharide that is normally synthesized by pancreatic and biliary ductal cells, as well as gastric, colon, endometrial, and salivary epithelia 2, 3. It is measured using a radioimmunometric assay 1.
Critical Limitation: Lewis Blood Group Dependency
Approximately 5% of the population who are genotypically Lewis a-b- cannot produce CA 19-9 antigen, making testing completely uninformative in these patients 1. This represents a fundamental biological limitation that cannot be overcome—these individuals will have false-negative results regardless of disease status.
Clinical Applications and Limitations
Not Recommended for Screening
CA 19-9 should NOT be used as a screening test for pancreatic cancer 1. The specificity and sensitivity are inadequate for accurate diagnosis in asymptomatic populations 1.
Lack of Specificity
CA 19-9 is elevated in multiple conditions beyond pancreatic cancer 1:
Malignant conditions:
- Upper gastrointestinal tract tumors
- Cholangiocarcinoma
- Colorectal cancer
- Ovarian cancer
- Hepatocellular carcinoma
Benign conditions:
- Inflammatory hepatobiliary diseases
- Biliary obstruction (both benign and malignant)
- Chronic pancreatitis
- Thyroid disease
This lack of specificity severely limits its diagnostic utility, with a positive predictive value of only 72.3% 3.
Where CA 19-9 Has Clinical Utility
Monitoring treatment response: CA 19-9 can be measured at baseline and every 1-3 months during active treatment for locally advanced or metastatic disease 1. Rising levels may indicate progressive disease, though confirmation with imaging or biopsy is mandatory—CA 19-9 elevation alone is insufficient evidence 1.
Prognostic information: Elevated preoperative CA 19-9 levels correlate with worse outcomes, and failure of levels to normalize postoperatively suggests residual disease 1. Recent data suggests that patients with >80% decrease in CA 19-9 and post-treatment levels <50 U/mL have the best 3-year survival after surgical exploration 4.
Common Pitfalls to Avoid
- Never use CA 19-9 alone to determine operability in pancreatic cancer—it requires correlation with imaging 1
- Never diagnose recurrence based solely on rising CA 19-9—always confirm with imaging or biopsy 1
- Remember that obstructive jaundice causes false-positive elevations in 10-60% of cases 5
- CA 19-9 may not be elevated in small pancreatic tumors, limiting sensitivity 1
Despite decades of research seeking better biomarkers, CA 19-9 remains the only validated tumor marker in widespread clinical use for pancreatic cancer, though it must be interpreted cautiously within the appropriate clinical context 3, 5.